MyFinsight
Home
Blog
About
Contact
Download
Download image
something is missing
$311,023K
Net loss
$117,345K
something is missing
$70,030K
Canceled cashflow
$193,678K
Accretion and
amortization of...
-$3,148K
Non-cash interest
expense
$2,036K
Other non-cash items
-$169K
Segment research and
development expense
-$161,800K
Share-based compensation
expense (see note 10)
-$18,924K
Net cash used in
operating activities
$132,983K
Canceled cashflow
$59,745K
Total operating
expenses
$116,189K
License
revenue-License
-$70,006K
Other items
$7,483K
Canceled cashflow
$180,724K
Net increase
(decrease) in cash and cash...
-$106,089K
Canceled cashflow
$132,983K
Purchases of marketable
securities
-$49,764K
Purchase of property and
equipment
-$232K
Proceeds from issuance of
common stock upon...
$2,750K
Share-based compensation
expense
-$18,924K
Accrued and other
liabilities
-$18,577K
Prepaid expenses and
other assets
$11,183K
Change in fair value of
derivative liability
$7,530K
Accounts payable
-$3,312K
Depreciation and
amortization
-$219K
something is missing
$265,858K
Segment selling,
general and...
$31,055K
Net cash provided by
investing activities
-$224,596K
Canceled cashflow
$49,996K
Net cash provided by
financing activities
-$14,476K
Canceled cashflow
$2,750K
Maturities of marketable
securities
-$274,592K
Proceeds from sale of
common stock in...
-$14,904K
Proceeds from the
exercise of warrants
-$1,618K
Proceeds from issuance of
common stock under...
-$1,120K
Back
Back
Cash Flow
Viridian Therapeutics, Inc. DE (VRDN)
Viridian Therapeutics, Inc. DE (VRDN)
source: myfinsight.com